Agency: Cordis | Branch: H2020 | Program: SGA-CSA | Phase: WIDESPREAD-1-2014 | Award Amount: 496.86K | Year: 2015
Existing European disparity in research and innovation performance is a barrier to competitiveness and growth. To overcome this disparity, the leading institute in molecular life sciences and three research universities of Hungary have joined forces forming a new Centre of Excellence for Molecular Medicine (HCEMM). These institutions have the necessary basic research and clinical portfolio to initiate a joint translational research program and eventually deliver high impact results. Engagement of the European Molecular Biology Laboratory and its long term experience in partnerships for molecular medicine provides guidance and technical support to achieve these goals, particularly bringing new research culture and management approaches including selection, regular evaluation and internationalization of independent groups. Joining of Hungary to EMBL by 2014 is a strong basis of this partnership. Commitment of the Hungarian Government towards establishment of HCEMM is clearly demonstrated by its coordinator role via the National Innovation Office which is responsible for research, development, innovation and the national S3 strategy. A joint management structure will be developed to assess basic research and clinical strengths of participating institutions, to identify key clinical areas of research where unmet medical needs exist and to pair basic research groups with clinical researchers to form translational research units for tackling these problems. All partners in the consortium will actively contribute to prepare a business plan of long-term sustainability and then to establish legal autonomy, location and proper resources of HCEMM. HCEMM is expected to demonstrate feasibility of the teaming concept by realizing synergistic research efforts that builds on the specific strengths of the participants and needs. Technological platforms will also be jointly established. Intense technology transfer, shared PhD and clinical research training will serve the key goals.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-06-2014 | Award Amount: 3.38M | Year: 2015
Despite the fact that iodine deficiency (ID) can easily be prevented by iodine fortification of table salt, industrial salt and cattle food, Europe belongs to the worst regions in terms of access to iodized salt and is seriously ID, resulting in the perpetuation of the single most important, preventable cause of brain damage. European ID is due to significant heterogeneity in prevention and monitoring programs, leading to inappropriate interventions, increased disease burden, health inequities and increased health care costs. Up to 360 Million European citizens are exposed to ID disorders. An effective European monitoring program is a crucial step towards eradication of ID disorders with significant benefits for European citizens and the sustainability of health care systems. The effects of ID in total cause tremendous, preventable costs in health care systems of affected regions. The overall aim of EUthyroid is to evaluate ID prevention and monitoring programs in 24 European countries, to initiate capacity building for harmonized European ID prevention and monitoring programs, and to disseminate project outcomes for supporting measures on national and EU level in order to eradicate ID disorders in Europe. The project will position itself as international hub of current national initiatives in the attempt to coordinate and support existing national activities. EUthyroid will generate the first harmonized data set of ID resulting in the first valid map of iodine status in Europe. With a dedicated dissemination program about the unfavorable health outcomes of ID, EUthyroid will pave the way for a harmonized EU-wide regulation of iodination, a common approach to iodine and outcome monitoring and establish recommendations for scientists on how to monitor IDD prevention programs. The project aims to make Europe a benchmark for ID disorder prevention worldwide.
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: REFLECTIVE-11-2015 | Award Amount: 1.90M | Year: 2016
Traditional valorisation approaches focus on linear processes: from academia to society. In order to bring valorisation to a higher level, all relevant actors need to cooperate in an equal setting: co-creation. Co-creation transcends boundaries, but it does not happen naturally. Therefore, the ACCOMPLISSH consortium, consisting of 14 universities from 12 countries (representing all the sub disciplines in SSH), will actively involve the other partners from the so called Quadruple Helix (industry, governments and societal partners) within the project. The project has chosen an Open Innovation approach. The ACCOMPLISSH project (Accelerate co-creation by setting up a multi-actor platform for impact from Social Sciences and Humanities) will create a platform for dialogue where not only universities are involved. The dialogue platform is organised in such a way that academia, industry, governments and societal partners equally contribute in identifying barriers and enablers of co-creation. The results from both practice and the theory of co-creation form the basis of the valorisation concept and will be tested in the project in a quadruple helix setting. This concept will be tested and developed in such a way that it is transferable, scalable and customized for academia, industry, governments and societal partners in the whole of Europe. The impact profile of SSH research could be far stronger and more visible than it currently is. There are significant barriers to the valorisation of SSH research which still need to be understood in detail. In order to push the envelope within universities, we acknowledge that next to SSH researchers, the research support officers are key players in valorisation of SSH research. The project will identify all barriers and enablers of co-creation in order to develop an innovative valorisation concept, which will foster knowledge exchange within the quadruple helix and strengthens the position of SSH research.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 6.00M | Year: 2015
GLORIA aims to prove that the addition of chronic low dose glucocorticoids (GC) to current antirheumatic therapy is highly cost-effective and safe in elderly patients with rheumatoid arthritis (RA). RA is a frequent (affecting > 2% of the elderly population), painful and disabling chronic disease with high societal costs. RA is associated with multiple comorbidities, polypharmacy and adverse events; these problems, together with challenges in compliance (adherence) are dramatically increased in the elderly population. About 50% of patients are chronically treated with low-dose glucocorticoids (GC) in combination with other antirheumatic drugs, but without good evidence on the balance of benefit and harm. Thus, existing guidelines and information on safety and efficacy of GC are inadequate. GLORIA will address these problems by conducting a large pragmatic trial: 800 elderly (>65y) RA patients receiving standard of care will be randomized to additionally receive 5 mg prednisolone daily or placebo for 2 years. Very liberal eligibility criteria will ensure representativeness to the target population, and most data will be collected from routine clinical practice, minimizing patient and physician load, and operating costs. A novel tool will monitor compliance; it can send personalized reminders to a patients smart device. The efficacy of this technology will be tested in a nested trial. Compliance and other characteristics will be entered into a model that will allow personalized risk and benefit assessment in the future. Qualitative research in patients and physicians of member states will explore expectations and challenges in guideline implementation. This information and the study results will enable an update to existing guidelines and patient information, in collaboration with guideline committees and regulatory agencies. Networking conferences will improve health technology assessment in the elderly in general.
Feel4Diabetes - Developing and implementing a community-based intervention to create a more supportive social and physical environment for lifestyle changes to prevent diabetes in vulnerable families across Europe
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: HCO-05-2014 | Award Amount: 3.00M | Year: 2014
The Feel4Diabetes project addresses HCO5-2014: Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes. The aim of this project is to develop, implement and evaluate a community-based intervention aiming to create a more supportive social and physical environment to promote lifestyle and behaviour change to prevent type 2 diabetes among families from low and middle income countries and from vulnerable groups in high income countries in Europe. Methods: The PRECEDE-PROCEED Model will provide the theoretical framework for the development, implementation and evaluation of the Feel4Diabetes intervention. The framework has two phases, namely the PRECEDE and PROCEED phase. During the PRECEDE phase, the target population as well as behaviours related to type 2 diabetes and their determinants will be identified. Existing research programs and guidelines for type 2 diabetes prevention, policies, legislation, local infrastructure and human resources will also be recorded. Based on the knowledge gained from this phase, a low-cost and applicable in low-resource settings community-based intervention programme will be developed, with the active engagement of local stakeholders, providing access to the existing infrastructure and human resources wherever feasible. During the PROCEED phase, the intervention will be implemented and its process, impact, outcome, cost-effectiveness and scalability will be evaluated. The results of the intervention will be disseminated, aiming to embed it into policy and practice. Consortium: The Feel4Diabetes multidisciplinary consortium incorporates the necessary expertise on diabetes prevention, behaviours, nutrition, physical activity, policy and health economics. It consists of 10 partners from 7 universities, 1 research institute, 1 advocacy group and a small-medium enterprise, representing European low-middle income, high income and under socioeconomic crisis countries.